User:Mr. Ibrahem/Pralsetinib

Pralsetinib, sold under the brand name Gavreto, is a medication used to treat non-small cell lung cancer (NSCLC) and thyroid cancer. It is used in advanced cases which are RET fusion-positive. It is taken by mouth.

Common side effects include constipation, high blood pressure, tiredness, muscle pain, low blood cells, liver problems, and low calcium. Other side effects may include pneumonitis, bleeding, tumor lysis syndrome, and poor wound healing. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor.

Pralsetinib was approved for medical use in the United States in 2020. In the United States it costs about 20,100 USD per month. It is not approved for use in the United Kingdom as of 2021.